On this page

Semaglutide is a medication that mimics an intestinal hormone called GLP-1. It is used to treat type 2 diabetes and obesity, and it may also improve metabolic dysfunction-associated fatty liver disease. Its main effects on the liver come through weight loss and better glucose control.

Recent studies show that semaglutide can also resolve inflammation from metabolic dysfunction-associated steatohepatitis (MASH) in a meaningful proportion of patients with fibrosis. This does not mean that everyone with fat on an ultrasound needs semaglutide. Before discussing medication, it is useful to assess fibrosis risk and decide whether there is an indication related to obesity, diabetes or MASH.

Why can it improve the liver?

GLP-1 receptor agonists reduce appetite, slow stomach emptying and improve the body’s response to insulin. As weight decreases, less fat reaches the liver and inflammation may improve.

This is not a “liver cleanse.” It is the result of measurable metabolic changes. Benefits are generally greater when medication is combined with a suitable diet, physical activity, and treatment of high blood pressure, abnormal lipids and diabetes.

What have studies shown?

In patients with MASH and moderate to advanced fibrosis, but without cirrhosis, clinical trials have found that steatohepatitis resolves more often with semaglutide than with placebo. Findings related to fibrosis are encouraging, although longer follow-up is needed.

Evidence is more limited in people with MASH-related cirrhosis. Semaglutide should not be viewed as a treatment that can reverse established cirrhosis, although it may be prescribed for diabetes or obesity in carefully selected patients.

Who may benefit?

Semaglutide may be considered for people with:

  • Obesity or overweight that meets a recognized medical indication.
  • Type 2 diabetes requiring better metabolic control.
  • MASH with significant fibrosis confirmed through an appropriate evaluation.

Fat on ultrasound alone is not enough. It is useful first to review liver enzymes, calculate FIB-4 and obtain elastography when appropriate.

Side effects and precautions

The most common side effects are nausea, early fullness, vomiting, diarrhea and constipation. They are often more noticeable when the dose increases. Gradual dose escalation under medical supervision can reduce these problems.

Extra caution is needed in people with a history of pancreatitis, gallbladder disease or severely delayed stomach emptying. Semaglutide is not recommended during pregnancy. Rapid weight loss can also reduce muscle mass unless protein intake and strength exercise are adequate.

What happens after stopping treatment?

Some of the lost weight may return after the medication is stopped. It is better viewed as part of sustained treatment for a chronic metabolic condition than as a short course. The decision to continue, change or stop it should be made with a clinician who knows your medical history.

Does it replace diet and exercise?

No. It can be a valuable tool, but it does not replace habits that protect liver and cardiovascular health. Nor does it replace fibrosis monitoring. A person may lose weight and still need follow-up if significant liver scarring was already present.

The useful question is not simply whether semaglutide “works for fatty liver,” but whether it offers a clear benefit for you at a reasonable risk and cost.

See also

References

  1. Bansal MB, Patton H, Morgan TR, et al. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340.
  2. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025;392(21):2089-2099.
  3. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024;391(4):299-310.
See more in Fatty liver

Related articles